In another positive development, Pfizer won a bid in a London court to invalidate two of GSK Plc’s GSK patents relating to its respiratorysyncytialvirus (RSV) vaccine. Also Read: UK Chooses ...
The complex shape of respiratory syncytial virus is one hurdle limiting the development of treatments for an infection that leads to hospitalization or worse for hundreds of thousands of people in the ...
A new COVID variant, XEC, is gaining traction in the U.S. and is estimated to account for up to 13% of cases. The strain is a recombinant of two JN.1 lineage viruses, with new COVID shots expected to ...
Respiratorysyncytialvirus (RSV) is a leading cause of severe illness in infants, with no effective treatment. Results of a phase 2 trial suggested that ziresovir may have efficacy in the ...
Some results have been hidden because they may be inaccessible to you